Some studies have demonstrated that tumor cells expressing advanced glycation end-product receptors bind HMGB1, activating nuclear factor kappa-B (NF-κB) signaling and inducing interleukin-8 (IL-8) release. The gene discussed is CXCL8; the disease is neoplasm.